Drugs / RSV preF-based Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05327816 | Apr 2022 → Jan 2023 | respiratory syncytial virus infectious disease | Janssen Vaccines & Prevention B.V. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV preF-based Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05327816 ↗ |
| Modality | Vaccine | “RSV preF-based vaccine will be administered as intramuscular injection.” NCT05327816 ↗ |
| Route | Intramuscular | “administered as intramuscular injection” NCT05327816 ↗ |